Sydney, June 23, 2026, 06:09 (AEST)
- Cochlear ended Monday at A$112.97, sliding 4.38% after it jumped 13.9% last week.
- Short interest was 6.09% of issued shares on June 16, near the highest level for the past year.
- The company said quantified currency, restructuring, receivable, and factory-cost effects make up about 58%-64% of the difference between its previous guidance floor and the new midpoint.
Cochlear Limited (ASX:COH) dropped 4.38% to A$112.97 on Monday after climbing for five straight sessions. There was no company announcement to drive the move. At press time, the ASX cash market was closed.
CSL dropped 2.96%, outpacing the S&P/ASX 200’s 0.14% dip. Pro Medicus finished up 1.06%. Healthcare names ended mixed. Cochlear saw 714,600 shares traded—roughly a third of the 2.14 million seen on Friday. Lighter volumes line up with profit-taking but don’t confirm it.
Cochlear shares had posted gains each day last week, picking up 13.9% from A$103.75 to A$118.14. Even after slipping Monday, the stock is still up 8.9% across the last seven sessions. Cochlear’s most recent price-sensitive update remains its April 22 profit warning. The company’s June 8 statement dealt with a major shareholder.
Positioning is also a factor. Short interest was 6.09% on June 16, climbing 1.23 percentage points in a week and just below its 6.21% high for the year. There are 65.4 million shares in total, so short sellers held around 4 million shares, about 6.6 times the displayed daily average. The ASIC data lags four days, but shows bears have been adding during the rebound, not doing much covering. That could mean a bigger swing in either direction.
Factory utilisation is the main issue. Back in April, Cochlear dropped its FY26 underlying net profit forecast to A$290 million-A$330 million, down from A$435 million-A$460 million, citing weaker developed-market demand and a stronger Australian dollar.
The company broke out up to A$10 million tied to Middle East receivables, around A$20 million from lower factory overhead recovery, A$18 million-A$25 million in restructuring costs, and A$25 million from currency moves. Altogether, those sum to between A$73 million and A$80 million—roughly 58% to 64% of the A$125 million difference from the old guidance floor to the new range’s midpoint at A$310 million. Excluding overlap, that puts A$45 million to A$52 million on weaker sales and other impacts not detailed.
Arithmetic still counts. “Overhead absorption” is just fixed factory costs spread over more units, so if implant volumes come back, the A$20 million drag could reverse and earnings could move up quicker than revenue. Morningstar analyst Lochlan Halloway kept his A$110 valuation on June 5, saying he’s “more optimistic than the market” on demand holding up and expects better factory-cost recovery if volumes rise. Monday’s close came in 2.7% higher than that number. Morningstar
Volume quality is an issue. Implant units were up 6% in the first half, but implant revenue stayed flat as more lower-priced emerging-market devices sold. Services revenue in the third quarter gained 13%, while acoustics was up 11% at constant currency, taking out the effect of exchange rates. That gave Cochlear some offset to weak new implants.
But the downside risk is still on the table. CEO Dig Howitt said adult and senior hearing care remains “a discretionary intervention,” and flagged that if US referrals stay weak, European surgery volumes don’t pick up, Middle East demand lags or the Aussie dollar doesn’t rebound, higher factory costs could stick around. Morningstar’s Shane Ponraj, who said “the market was blindsided” by the April warning, is calling for “lower earnings growth for longer.” ASX Announcements
Cochlear heads into Tuesday with traders watching to see if Monday’s drop was just profit-taking or signals more downside. The company doesn’t report until August 18. Any updates in delayed short-interest numbers and any signs of stronger factory utilisation could drive moves in the stock before then.
